全文获取类型
收费全文 | 62553篇 |
免费 | 4031篇 |
国内免费 | 1250篇 |
专业分类
耳鼻咽喉 | 241篇 |
儿科学 | 2138篇 |
妇产科学 | 755篇 |
基础医学 | 3826篇 |
口腔科学 | 517篇 |
临床医学 | 8442篇 |
内科学 | 19729篇 |
皮肤病学 | 187篇 |
神经病学 | 895篇 |
特种医学 | 1011篇 |
外国民族医学 | 1篇 |
外科学 | 7419篇 |
综合类 | 9751篇 |
现状与发展 | 3篇 |
预防医学 | 3434篇 |
眼科学 | 85篇 |
药学 | 5795篇 |
50篇 | |
中国医学 | 2828篇 |
肿瘤学 | 727篇 |
出版年
2024年 | 124篇 |
2023年 | 1013篇 |
2022年 | 1901篇 |
2021年 | 2568篇 |
2020年 | 2462篇 |
2019年 | 2177篇 |
2018年 | 2114篇 |
2017年 | 1937篇 |
2016年 | 2007篇 |
2015年 | 2129篇 |
2014年 | 4454篇 |
2013年 | 4662篇 |
2012年 | 3550篇 |
2011年 | 4116篇 |
2010年 | 3227篇 |
2009年 | 3228篇 |
2008年 | 3122篇 |
2007年 | 3137篇 |
2006年 | 2771篇 |
2005年 | 2596篇 |
2004年 | 2008篇 |
2003年 | 1690篇 |
2002年 | 1357篇 |
2001年 | 1288篇 |
2000年 | 945篇 |
1999年 | 864篇 |
1998年 | 696篇 |
1997年 | 648篇 |
1996年 | 593篇 |
1995年 | 530篇 |
1994年 | 540篇 |
1993年 | 387篇 |
1992年 | 348篇 |
1991年 | 332篇 |
1990年 | 294篇 |
1989年 | 293篇 |
1988年 | 273篇 |
1987年 | 209篇 |
1986年 | 182篇 |
1985年 | 176篇 |
1984年 | 148篇 |
1983年 | 85篇 |
1982年 | 110篇 |
1981年 | 91篇 |
1980年 | 77篇 |
1979年 | 80篇 |
1978年 | 62篇 |
1977年 | 60篇 |
1976年 | 52篇 |
1973年 | 29篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
33.
34.
《Vaccine》2016,34(24):2663-2670
Human metapneumovirus (HMPV) is a major cause of morbidity and mortality from acute lower respiratory tract illness, with most individuals seropositive by age five. Despite the presence of neutralizing antibodies, secondary infections are common and can be severe in young, elderly, and immunocompromised persons. Preclinical vaccine studies for HMPV have suggested a need for a balanced antibody and T cell immune response to enhance protection and avoid lung immunopathology. We infected transgenic mice expressing human HLA-A*0201 with HMPV and used ELISPOT to screen overlapping and predicted epitope peptides. We identified six novel HLA-A2 restricted CD8+ T cell (TCD8) epitopes, with M39–47 (M39) immunodominant. Tetramer staining detected M39-specific TCD8 in lungs and spleen of HMPV-immune mice. Immunization with adjuvant-formulated M39 peptide reduced lung virus titers upon challenge. Finally, we show that TCD8 from HLA-A*0201 positive humans recognize M39 by IFNγ ELISPOT and tetramer staining. These results will facilitate HMPV vaccine development and human studies. 相似文献
35.
Altan Ahmed John A. Stauffer Jordan D. LeGout Justin Burns Kristopher Croome Ricardo Paz-Fumagalli Gregory Frey Beau Toskich 《Journal of gastrointestinal oncology.》2021,12(2):751
BackgroundNeoadjuvant yttrium-90 transarterial radioembolization (TARE) is increasingly being used as a strategy to facilitate resection of otherwise unresectable tumors due to its ability to generate both tumor response and remnant liver hypertrophy. Perioperative outcomes after the use of neoadjuvant lobar TARE remain underinvestigated.MethodsA single center retrospective review of patients who underwent lobar TARE prior to major hepatectomy for primary or metastatic liver cancer between 2007 and 2018 was conducted. Baseline demographics, radioembolization parameters, pre- and post-radioembolization volumetrics, intra-operative surgical data, adverse events, and post-operative outcomes were analyzed.ResultsTwenty-six patients underwent major hepatectomy after neoadjuvant lobar TARE. The mean age was 58.3 years (17–88 years). 62% of patients (n=16) had primary liver malignancies while the remainder had metastatic disease. Liver resection included right hepatectomy or trisegmentectomy, left or extended left hepatectomy, and sectorectomy/segmentectomy in 77% (n=20), 8% (n=2), and 15% (n=4) of patients, respectively. The mean length of stay was 8.3 days (range, 3–33 days) and there were no grade IV morbidities or 90-day mortalities. The incidence of post hepatectomy liver failure (PHLF) was 3.8% (n=1). The median time to progression after resection was 4.5 months (range, 3.3–10 months). Twenty-three percent (n=6) of patients had no recurrence. The median survival was 28.9 months (range, 16.9–46.8 months) from major hepatectomy and 37.6 months (range, 25.2–53.1 months) from TARE.ConclusionsMajor hepatectomy after neoadjuvant lobar radioembolization is safe with a low incidence of PHLF. 相似文献
36.
37.
38.
39.
40.